229,000
TB incidence in 2022
62,000
drug-resistant TB incidence in 2022
24,300
deaths from TB in 2022
The Union's Offices
The Union’s headquarters in Paris is the global cornerstone of the organisation, taking on a coordinating role, sets policy and provides financial oversight of the organisation. The Union Switzerland Office, based in Geneva, acts as the political convenor for The Union, working at a strategic level to influence global health policy through high-level discussion and partnership.
The Union Headquarters in Paris
2 Rue Jean Lantier
75001 Paris
France

The Union Switzerland Office
Chemin Valmont 224
1260 Nyon
Switzerland
Members of The Union Europe Region
The Union is divided into seven regions to provide a platform for addressing lung health and related issues from a regional perspective. This structure offers members opportunities to network with colleagues who face the same regional challenges and contributes to The Union's deep understanding of local issues.
The Union Europe Region is made up of individuals and organisations.
Members in Europe initiated the first dedicated region Scientific Track, held at the Union World Conference on Lung Health. The sessions, developed in partnership with members of The Union’s Europe Region, shared experiences and challenges that are specific to the continent and invited delegates to focus on TB and lung health concerns that are particularly pressing in Europe.
UNION NEWS FROM THE Europe REGION
A year in review – evaluating the launch of IJTLD OPEN
An Editorial in a forthcoming issue of IJTLD OPEN describes how open access has driven a dramatic increase in visibility.
Update on IJTLD OPEN: the future is open
An Editorial in a forthcoming issue of IJTLD OPEN provides highlights of progress made to date and the benefits of open access publishing.
Loss to follow-up among adults with drug-resistant TB in Papua New Guinea
An article in a forthcoming issue of PHA assesses the reasons for loss-to-follow-up in patients being treated for disease resistant TB.